Find a Clinical Trial

Showing 181 - 190 of 196 Trials

  • Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05735184

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the safe dose of ziftomenib to be used in combination with other drugs to treat acute myeloid leukemia. Another purpose is to determine how well ziftomenib works in combination with the other drugs for acute myeloid leukemia. Ziftomenib has not been approved by Food and Drug Administration (FDA). Ziftomenib is an experimental drug may help in preventing or slowing the leukemia cells from growing and dividing. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have life expectancy greater than 3 months - Must not be diagnosis...

  • Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04855656

    Population:

    Adult

    Phase:

    I
    The purpose of this research study is to test how safe RP-6306 is at different doses and schedules, test how well RP-6306 works to shrink cancer in the body, and evaluate if food affects the way RP-6306 moves through your body. This study will test the investigational drug, RP-6306, for the first time in humans. “Investigational” means that the study drug being tested has not been approved by the United States Food and Drug Administration (FDA). RP- 6306 is a PKMYT1 inhibitor (blocks the activity of the PKMYT1 protein) that is designed to stop certain cancer cells from growing...

  • R5458-ONC-2012:PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTICD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05137054

    Population:

    Adult

    Phase:

    I
    This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? - Are you likely to live for at least six more months? -Do you have measurable disease as defined in the protocol according to International Myeloma Working Group (IMWG)...

  • Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A PilotStudy

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06673329

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...

  • DISRUPT: Aim 2

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05146297

    Population:

    Adult

    Phase:

    NA
    That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC...

  • Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills after Cancer-Related Surgery

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05585788

    Population:

    Adult

    Phase:

    NA
    - Are you of 18 years or older? - Do you have upcoming open, non-laparoscopic surgery? - Is it planned that you will receive opioids in the post-operative period? - Are you able to download and use a iPhone or iPad application? Are you Eligible? (Inclusion Criteria) Are you of 18 years or older? Do you have upcoming open, non-laparoscopic surgery? Is it planned that you will receive opioids in the post-operative period? Are you able to download and use a iPhone or iPad application?

  • Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma

    Principal Investigator:

    Lisa Ann Kachnic, MD, FASTRO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05838391

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to find out if performing adaptive planning during the treatment anal cancer will decrease the dose of radiation to normal organs and decrease the side effects. In this study, subjects will have a daily adjustment (adaptation) of their radiation plan as the tumor changes during the radiation treatment. The radiation will be given as part the standard of care treatment with chemotherapy, known as chemo-RT (CRT). Are you Eligible? (Inclusion Criteria) To be considered for this study, you must: 1. Have invasive anal cancer confirmed with biopsy 2. Be greater than 18...

  • IMPACT Trial: Intervention to iMProve AdherenCe equitably

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05496829

    Population:

    Adult

    Phase:

    NA
    Many patients with breast cancer, who also take medicine to prevent heart disease such as a blood pressure medicine or a cholesterol medicine, experience frustration with the large number and difficult scheduling of their medications, known as “pill burden”. This study will help us find out how much “pill burden” exists in subjects with cancer at various stages, and how this intervention can help. Results of this study may help us figure out the best way to help patients manage their medications in the future. Are you Eligible? (Inclusion Criteria) Are you diagnosed...

  • Improving Medications Adherence Equitably among Patients with Metastatic Breast Cancerand Cardiovascular Disease

    Principal Investigator:

    Claire Sathe, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06121453

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to evaluate the effect of a multi-part intervention to reduce barriers to medication use. All subjects who are enrolled in the study will undergo the following interventions: 1) A complete medication reconciliation will be done where you will be asked about all current medication you have been prescribed. This is to create an accurate list of current medications you are taking. 2) A two-time visit with a pharmacist to review all the medicines you take, reasons for not taking medicines, and to create a personalized plan to help you take your medicines. After 4...

  • Nitrous Oxide For Endoscopic Ablation of Refractory Barrett’s Esophagus (NO FEAR-BE)

    Principal Investigator:

    Julian Adin Abrams, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03554356

    Population:

    Adult

    Phase:

    NA
    dy is to evaluate the safety and effectiveness of using the C2 CryoBalloon Focal Ablation System to treat any remaining Barrett’s Esophagus after receiving Radiofrequency Ablation (RFA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? Do you have a history of esophageal cancer? Are you willing to undergo an experimental treatment for your type of cancer?

Pages